Journal article
Validity of the PROMIS-29 in a large Australian cohort of patients with systemic sclerosis
K Morrisroe, W Stevens, M Huq, J Sahhar, GS Ngian, J Zochling, J Roddy, S Proudman, M Nikpour, C Hill, S Lester, P Nash, M Rischmueller, G Strickland, V Thakkar, J Walker
Journal of Scleroderma and Related Disorders | WICHTIG PUBLISHING | Published : 2017
DOI: 10.5301/jsrd.5000243
Abstract
Background: We aimed to evaluate the construct validity of the Patient-Reported Outcomes Measurement Information System 29 (PROMIS-29) in Australian systemic sclerosis (SSc) patients. Methods: SSc patients, identified through the Australian Scleroderma Cohort Study database, completed two quality-of-life instruments concurrently, the PROMIS-29 and the Medical Outcomes Study 36-Item Short Form Health Survey (SF-36). The construct validity of the PROMIS-29 was assessed by the correlations between the PROMIS-29 and the SF-36 and Health Assessment Questionnaire Disability Index (HAQ-DI). Cronbach’s alpha was used to test the internal reliability of all instruments in Australian SSc patients and ..
View full abstractGrants
Awarded by NHMRC
Funding Acknowledgements
This work was supported by Scleroderma Australia, Arthritis Australia, Actelion Australia, Bayer, CSL Biotherapies, GlaxoSmithKline Australia and Pfizer. Dr. Morrisroe holds an NHMRC Scholarship (APP1113954). Dr. Nikpour holds an NHMRC Fellowship (APP1071735).